However, its impact on weight change may not be directly related to its dosage, so higher doses arent necessarily more effective
Coverage gaps, steep out-of-pocket costs, and payer-imposed roadblocks stall progress before treatment even begins, while stigma, fragmented care, and shifting patient perceptions chip away at long-term adherence
Its the first and only GLP-1 receptor agonist, making it a prolific development by Novo Nordisk
Patients are tarred with being responsible for their own weight gain but are denied any support offered to genuinely obese patients
On a standard 1mL syringe, the markings between 0 and 10 units can be hard to read accurately
References Gadde K.M., et al., Obesity: Pathophysiology and Management